BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in...
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion...
First Wave Announces Completion of Combination with ImmunogenX
First Wave to Participate In ˜Fireside Chat at the 36th Annual Roth Conference
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (œFirst Wave BioPharma or the œCompany), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (œFirst Wave BioPharma or the œCompany), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Sequire Investor Summit 2024, which is planned for January 23-25, 2024, at Condado Vanderbilt Hotel in San Juan, Puerto Rico.